2′-Deoxy-4′-C-Ethynyl-2-Fluoroadenosine: A Nucleoside Reverse Transcriptase Inhibitor with Highly Potent Activity Against Wide Spectrum of HIV-1 Strains, Favorable Toxic Profiles, and Stability in Plasma-Reference-Cited by-同舟云学术

2′-Deoxy-4′-C-Ethynyl-2-Fluoroadenosine: A Nucleoside Reverse Transcriptase Inhibitor with Highly Potent Activity Against Wide Spectrum of HIV-1 Strains, Favorable Toxic Profiles, and Stability in Plasma

Published:2007-11-26 Issue:10-12 Volume:26 Page:1543-1546
ISSN:1525-7770
Container-title:Nucleosides, Nucleotides and Nucleic Acids
language:en
Short-container-title:Nucleosides, Nucleotides and Nucleic Acids

Author:

Ohrui Hiroshi,Kohgo Satoru,Hayakawa Hiroyuki,Kodama Eiichi,Matsuoka Masao,Nakata Tomohiro,Mitsuya Hiroaki

Publisher

Informa UK Limited

Subject

Genetics,Molecular Medicine,Biochemistry,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/15257770701545218

Reference9 articles.

1. Synthesis and Biological Evaluation of 4′-C-Methyl Nucleosides

2. Antileukemic Activities and Mechanism of Action of 2′-Deoxy-4′-methylcytidine and Related Nucleosides

3. 4′-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro

4. 4 -C-Substituted-2 -Deoxynucleosides A Family of Antiretroviral Agents Which are Potent Against Drug-Resistant HIV Variants.

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Islatravir: evaluation of clinical development for HIV and HBV;Expert Opinion on Investigational Drugs;2024-01-26

2. Evaluating Multienzyme Cascade Routes for Pharmaceutically Relevant Molecules;European Journal of Organic Chemistry;2024-01-19

3. HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes;Viruses;2023-09-25

4. Biocatalytic cascade process of islatravir: Analytical and regulatory control strategy of minor enantiomer;Journal of Pharmaceutical and Biomedical Analysis;2023-09

5. HIV-1 resistance to islatravir/tenofovir combination therapy in wild-type or NRTI resistant strains of diverse HIV-1 subtypes;2023-06-18